Target intelligence / Profile preview

Natural killer group 2 member D ligands (NKG2DLs) (NKG2DL)

Target
NKG2DL
Molecular classification
MHC class I-related protein, Cell surface ligand
01

Overview

Natural killer group 2 member D ligands (NKG2DLs) are a group of cell surface proteins, including MHC class I polypeptide-related sequence A (MICA), MICB, and the UL16-binding protein (ULBP) family, that serve as critical markers of cellular stress. These ligands are typically absent or expressed at low levels on healthy cells but are significantly upregulated in response to viral infection, DNA damage, or malignant transformation [1] (PMID: 14502289). NKG2DLs are recognized by the activating receptor NKG2D, which is expressed on Natural Killer (NK) cells, CD8+ T cells, and γδ T cells, leading to the targeted destruction of the ligand-expressing cells [2] (PMID: 9497295). In the context of oncology, the broad expression of these ligands across diverse tumor types makes them a compelling target for immunotherapies, such as CAR-T cells (e.g., CYAD-01) and bispecific antibodies [3] (PMID: 30305461). However, a major challenge in targeting NKG2DLs is the tumor-mediated shedding of these proteins from the cell surface, which creates soluble decoys that inhibit immune cell function and facilitate immune evasion [4] (PMID: 18836474). Current research aims to stabilize these ligands on the cell surface or use them as anchors for multi-specific immune engagers to enhance anti-tumor efficacy.

Other names
MHC class I polypeptide-related sequence A (MICA)MHC class I polypeptide-related sequence B (MICB)UL16-binding proteins (ULBP1-6)Stress-induced ligandsNK-activating ligandsAbnormal/stressed patient cells expressing NK-activating ligands
02

Mechanism of action

Binding to the NKG2D activating receptor on effector lymphocytes (NK cells, CD8+ T cells) to trigger cell-mediated lysis of the ligand-expressing target cell.

03

Biological functions

Immune responseCell-mediated cytotoxicityStress responseSignal transduction
04

Disease associations

CancerInfectionAutoimmune disease
05

Safety considerations

On-target off-tumor toxicity (expression on healthy stressed cells)Immune evasion via proteolytic shedding of ligandsCytokine release syndrome (CRS)
06

Interacting drugs

CYAD-01

3 more in the full profile.

07

Biomarkers

Surface expression of MICA/BSurface expression of ULBPsSoluble MICA (sMICA) serum levels

Beyond the preview

Go deeper on Natural killer group 2 member D ligands (NKG2DLs) (NKG2DL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural killer group 2 member D ligands (NKG2DLs) (NKG2DL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call